Mutation in CDC42 Gene Set as a Response Biomarker for Immune Checkpoint Inhibitor Therapy

Mutation in CDC42 Gene Set as a Response Biomarker for Immune Checkpoint Inhibitor Therapy

ABSTRACT Background Immune checkpoint inhibitors (ICIs) have achieved great success; however, a subset of patients exhibits no response. Consequently, there is a critical need for reliable predictive biomarkers. Our focus is on CDC42, which stimulates multiple signaling pathways promoting tumor grow...

Full description

Saved in:
Bibliographic Details
Main Authors: Kun Wang, Yingying Zhang, Zhaoming Su, Bei Wang, Yuanyang Zhou, Xiaochu Tong, Chengying Xie, Xiaomin Luo, Sulin Zhang, Mingyue Zheng
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Cancer Medicine
Subjects:
biomarker
CDC42
clinical response
immunotherapy
pan‐cancer
Online Access:https://doi.org/10.1002/cam4.70556
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.70556

Similar Items